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Aim The aim of this study was to investigate the relationship between gender and survival of patients with heart failure,
using data from both randomized trials and observational studies, and the relative contribution of age, left ventricular
systolic function, aetiology, and diabetes to differences in prognosis between men and women.
Methods
and results
Data from 31 studies (41 949 patients; 28 052 men, 13 897 women) from the Meta-Analysis Global Group In Chronic
Heart Failure (MAGGIC) individual patient meta-analysis were used. We performed survival analysis to assess the
association of gender with mortality, adjusting for predictors of mortality, including age, reduced or preserved ejec-
tion fraction (EF), and ischaemic or non-ischaemic aetiology. Women were older [70.5 ( standard deviation 12.1) vs.
65.6 (standard deviation 11.6) years], more likely to have a history of hypertension (49.9% vs. 40.0%), and less likely to
have a history of ischaemic heart disease (46.3% vs. 58.7%) and reduced EF (62.6% vs. 81.6%) compared with men.
During 3 years follow-up, 3521 (25%) women and 7232 (26%) men died. After adjustment, male gender was an in-
dependent predictor of mortality, and the better prognosis associated with female gender was more marked in
patients with heart failure of non-ischaemic, compared with ischaemic, aetiology (P-value for interaction ¼ 0.03)
and in patients without, compared with those with, diabetes (P-value for interaction ,0.0001).
Conclusion This large, individual patient data meta-analysis has demonstrated that survival is better for women with heart failure
compared with men, irrespective of EF. This survival benefit is slightly more marked in non-ischaemic heart failure but
is attenuated by concomitant diabetes.
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Introduction
While the populations of patients with heart failure (HF) studied in
clinical trials are dominated by men, in routine clinical practice half
or more of all patients with HF are women.1,2 Whether prognosis
differs for men and women with HF is controversial. Many studies
have associated female sex with better survival,1– 14 although
several failed to identify such an association15– 18 and one study
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has reported worse prognosis for women.19 Moreover, in HF
populations, sex is strongly associated with a number of clinical
variables that influence prognosis such as age, aetiology, and in par-
ticular left ventricular ejection fraction (EF), associations which
may confound the independent effect of sex on survival. Assess-
ment of the relationship between sex and prognosis is further
complicated by the relatively small numbers of women in rando-
mized, controlled trials involving patients with HF, in large part
due to the exclusion from these trials of older patients and patients
with HF with preserved EF, both of which are more prevalent
among women with HF.
The potential reasons for differences in survival for men and
women with HF are uncertain. Differences in survival between
men and women with HF fail to show a consistent relationship
to either aetiology (ischaemic or non-ischaemic)2,3,9 or to
whether patients had reduced or preserved EF.1,10–12 The
greater prevalence of diabetes20223 and the relative under-use of
evidence-based therapies among women compared with men
with HF14,24,25 may theoretically contribute to worse prognosis
for women. However, HF with preserved EF is more common
among women than men, and this may be expected to lead to
better survival for these patients.26
The main results from the Meta-Analysis Global Group In
Chronic Heart Failure (MAGGIC) meta-analysis demonstrated
that HF patients with preserved EF have a lower risk of death
than patients with reduced EF, regardless of age, sex, and aetiology
of HF.27 The main analysis also showed that male sex was an inde-
pendent predictor of mortality [hazard ratio (HR) 1.23, 95% con-
fidence interval (CI) 1.18–1.28].27 The aim of the current analysis
was to assess comprehensively the relationship between sex and
survival in patients with HF, using a large individual patient data
set. Our hypothesis was that age, left ventricular EF, aetiology,
and diabetes would have a different impact on survival for men
and women with HF.
Methods
The methods and main results from the MAGGIC meta-analysis have
already been described.26,27 In brief, we searched online databases
using the key words: incidence, prognosis, outcome, mortality, clinical
trials, HF, ventricle, EF, systolic, and diastolic. We also searched refer-
ence lists of articles obtained during the online search, as well as con-
ference abstracts, and utilized personal communication. Eligible studies
were those that included patients with HF and reported outcome
(death from any cause). Studies that applied a left ventricular EF
entry criterion were excluded. The meta-analysis was approved by
The University of Auckland Human Subjects Ethics Committee.
Fifty-six potentially suitable studies were identified, and individual
patient data were provided from 31 studies on a pre-defined set of
variables including demographics, medical history, medical treatment,
symptomatic status, clinical variables, laboratory variables, and
outcome. Data from the individual studies were re-coded into a
uniform format at the Central Co-ordinating Centre at the University
of Auckland and incorporated into one database. The data from the
Candesartan in Heart Failure Assessment of Reduction in Mortality
and morbidity (CHARM)6 trial were made available for this
meta-analysis, but the data set from this study was added at the
London School of Hygiene and Tropical Medicine and the final analyses
run again incorporating these data. The results from the MAGGIC
meta-analysis demonstrated that patients with HF with preserved left
ventricular EF have lower risk of death from any cause than patients
with reduced left ventricular EF.
Statistical analysis
For the current analyses, Cox proportional hazards models were used
to estimate the risk of death from any cause within 3 years for men
compared with women. All models were adjusted for age, aetiology
(ischaemic vs. non-ischaemic), left ventricular EF [reduced (defined
as EF ,50%) vs. preserved], history of hypertension, diabetes, and
atrial fibrillation, and stratified by study. Cox models adjusted for age
were used to plot mortality curves.
Interactions between sex and the remaining covariates were
explored. All covariates were dichotomous except for age, which
was left as a continuous variable. Statistically significant interactions
(interaction P-value ,0.05) prompted subgroup analyses that
focused on the relationship between sex and the covariate, within
the EF group. For clarity, these models were only adjusted for age
and stratified by study.
The correlation between scaled Schoenfeld residuals and length of
follow-up showed that there was no violation of the proportional
hazards assumption for all analyses. Analyses were performed using
SAS v 9.2 (SAS Institute Inc., Cary, NC, USA).
Role of the funding source
The sponsors of the study had no role in the study design, data analysis
or interpretation, or writing of the report. The corresponding author
had full access to all the data in the study and had final responsibility for
the decision to submit the manuscript for publication.
Results
Data were available from 31 studies involving a total of 54 416
patients. Of these, 1179 patients were excluded from the analysis
due to irresolvable dates or having died during an index hospital
admission, 2246 based on aetiology of HF (either valvular heart
disease or hypertrophic cardiomyopathy), 9019 due to missing in-
formation on left ventricular EF, and 23 due to missing information
on sex. Thus, the main analysis was based on 41 949 patients;
28 052 (67%) men and 13 897 (33%) women.
The baseline characteristics of the study population are shown
in Table 1. When compared with men, women were older {70.5
[standard deviation (SD) 12.1] vs. 65.6 [SD 11.6] years}, more
commonly had a history of hypertension (49.9% vs. 40.0%), and
less commonly had a reduced EF (62.6% vs. 81.6%). Women had
more severe functional limitation than men, with a greater propor-
tion of women than men in New York Heart Association (NYHA)
class III or IV. Mean heart rate was also higher in women. Overall,
women were prescribed angiotensin-converting enzyme (ACE)
inhibitors or angiotensin receptor blockers (ARBs) and beta-
blockers less frequently than men. The under-use in women of
these treatments was particularly evident in patients with
reduced EF (ACE inhibitors or ARBs 79.0% vs. 84.6%; beta-blocker
36.2% vs. 39.7%).
Survival
During 3 years follow-up, 3521 (25.3%) women and 7232 (25.7%)
men died. There were 137 [95% confidence interval (CI) 133–
140] deaths per 1000 patient-years in men and 135 (95% CI
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131–139) deaths per 1000 patient-years in women. On analysis
only adjusted for age, men were at higher risk of death than
women [hazard ratio (HR) 1.31, 95% CI 1.25–1.36] (Figure 1).
As previously reported, on multivariable analysis, male sex
showed an independent association with the risk of death at 3
years (HR 1.23, 95% CI 1.18–1.28).27 When the randomized con-
trolled trials of pharmacotherapy (three trials, 20 878 patients)
were excluded from the analysis, the risk of death remained
higher among men (fully adjusted HR 1.27, 95% CI 1.19–1.36).
Age, left ventricular ejection fraction, and
hypertension
The excess mortality risk associated with male sex was of similar
magnitude in patients with reduced or preserved EF (Figure 2).
Neither age (P ¼ 0.63) nor history of hypertension (P ¼ 0.10)
altered the differential relationship between sex and outcome.
However, both diabetes (P, 0.001) and aetiology of HF (P ¼
0.03) did appear to modify this relationship.
Figure 1 All-cause mortality for men and women adjusted for
age (P, 0.001).
Figure 2 All-cause mortality for men and women with heart
failure and preserved ejection fraction (HF-PEF) or reduced ejec-
tion fraction (HF-REF) adjusted for age (EF group × gender inter-
action P ¼ 0.72).
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Table 1 Baseline characteristics of 41 949 patients included in 31 studies by gender
Men Women P-value
n (31 studies) 28 052 13 897
Age, years (SD) 65.6 (11.6) 70.5 (12.1) ,0.001
Medical history
Hypertension 40.0 49.9 ,0.001
Myocardial infarction 51.0 33.3 ,0.001
Atrial fibrillation 19.7 21.6 ,0.001
Diabetes 22.8 25.4 ,0.001
Ischaemic aetiology 58.7 46.3 ,0.001
Medication
ACE inhibitor or ARB 80.3 71.1 ,0.001
Beta-blocker 38.5 34.7 ,0.001
Diuretic 80.2 83.6 ,0.001
Spironolactone 22.5 20.9 0.004
Digoxin 44.2 41.2 ,0.001
Clinical status
Functional class (I/II/III/IV) 11.1/47.4/34.7/6.8 9.1/45.2/36.7/9.0 ,0.001
Heart rate, b.p.m. 78.0 (17.5) 81.4 (19.6) ,0.001
SBP, mmHg 128.6 (21.7) 135.0 (24.5) ,0.001
DBP, mmHg 76.9 (12.2) 77.0 (13.2) 0.3245
Left ventricular EF, % 33.0 (24.5–44.0) 42.0 (30.0–57.0) ,0.001
Preserved EF, % 18.4 37.4 ,0.001
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; DBP, diastolic blood pressure; EF, ejection fraction; SBP, systolic blood pressure; SD, standard deviation.
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Diabetes
Diabetes was present more frequently in women (25.4%) than in
men (22.8%, P, 0.001). In patients with reduced EF, diabetes
was present among 26.6% of women and 23.1% of men (P,
0.001), and in patients with preserved EF, among 23.6% of
women and 21.7% of men (P ¼ 0.03). There were 2997 deaths
among 9776 patients (30.7%) with, and 7366 deaths among 31
513 patients (23.4%) without, diabetes. After adjustment for cov-
ariates, diabetes retained an independent association with death
from any cause (adjusted HR 1.41, 95% CI 1.35–1.47) and with
cardiovascular death (HR 1.51, 95% CI 1.41–1.62).
Concomitant diabetes attenuated the lower risk of death asso-
ciated with female sex (risk of death for men vs. women: diabetes
HR 1.11, 95% CI 1.03–1.20; no diabetes 1.37, 95% CI 1.30–1.45,
P-value for interaction ,0.0001). Diabetes also appeared to
modify the relationship between sex and mortality, irrespective
of left ventricular EF. Among patients with diabetes, there was
no statistically significant difference in the HR for death from any
cause between men and women in either the preserved or
reduced EF groups. However, for patients without diabetes, men
had a higher risk of death from any cause compared with
women, in both the preserved and reduced EF groups. The
adjusted HR for different subgroups, with women with preserved
EF and no diabetes as the comparator, is shown in Figure 3A.
The three-way interaction for gender × EF × diabetes was not
statistically significant (P ¼ 0.208).
Aetiology
Ischaemic aetiology was less frequent among women (46.3%) than
men (58.7%, P, 0.001). Ischaemic aetiology was recorded in
61.4% of men and 50.9% of women (P, 0.001) with reduced
EF, and in 46.9% of men and 38.6% of women (P, 0.001) with
preserved EF. Ischaemic aetiology showed an independent
Figure 3 (A) Risk of death of heart failure (HF) patients by sex, diabetes mellitus (DM), and ejection fraction group (preserved HF-PEF or
reduced HF-REF) adjusted for age and stratified by study (gender × EF group × diabetes interaction P ¼ 0.208). (B) Risk of death of HF patients
by sex, aetiology, and ejection fraction group (HF-PEF or HF-REF) adjusted for age and stratified by study (gender × EF group × ischaemic
aetiology interaction P ¼ 0.0008). CI, confidence interval.
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association with death from any cause (adjusted HR 1.07, 95% CI
1.03–1.12), and cardiovascular death (HR 1.11, 95% CI 1.04–1.19).
The aetiology of HF appeared to modify the association
between sex and outcome: risk of death for men vs. women
with ischaemic HF, adjusted HR 1.17 (95% CI 1.10–1.24); non-
ischaemic aetiology HR 1.28 (95% CI 1.21–1.37), P-value for
interaction ¼ 0.03. Although there was a trend to worse prognosis
in men with ischaemic aetiology, this did not reach statistical signifi-
cance in either the preserved or reduced EF groups. For patients
with non-ischaemic aetiology, men had a higher risk of death
from any cause compared with women, in both the preserved
and reduced EF groups. The adjusted HR for the different sub-
groups compared with women with preserved EF and no ischaemic
HF is shown in Figure 3B (three-way gender × EF × ischaemic aeti-
ology interaction P ¼ 0.0008).
Discussion
This large-scale meta-analysis, based upon patient-level data from
almost 42 000 individuals, represents the largest assessment of
the association between sex and survival for patients with HF.
The main finding of our study is that compared with men,
women with HF have lower all-cause mortality over 3 years, irre-
spective of EF. Our analysis confirms that women with HF are on
average older, are more likely to have a history of hypertension
and diabetes, but are less likely to have HF of ischaemic aetiology.
We also found that women had more severe functional limitation
than men as reflected by NYHA class. Importantly, women were
less likely than men to be prescribed evidence-based therapies,
particularly among those patients with HF with reduced EF, for
which there is unequivocal evidence of benefit from these agents.
Previous studies assessing potential differences in survival among
men and women with HF have presented conflicting results, with
some suggesting better survival for women1214 and others failing
to identify such an association.15218 Many of these studies have
been limited by relatively small numbers of patients and have pre-
sented mortality risks for men and women with wide and overlap-
ping confidence intervals, preventing definitive conclusions from
being drawn. Moreover, consideration of specific interactions of
sex with aetiology of HF or with reduced/preserved EF has been
limited. Our study, using a large individual patient data set, is appro-
priately powered to ascertain the prognostic significance of sex in
patients with HF.
The current analysis suggests that while crude unadjusted mor-
tality rates in men and women were very similar, when adjusted for
age the risk of death was higher in men than in women with HF.
Further, the influence of age on survival was similar in men and
women (P for gender × age interaction ¼ 0.63), suggesting that
better survival in women is associated with factors other than
age. While women have a higher prevalence of HF with preserved
EF which was associated with a better prognosis in this study, we
observed a higher risk of death in men, irrespective of whether
they had HF with reduced or preserved EF (Figure 2).
There are a number of alternative potential explanations for the
better outcomes in women with HF. The female heart appears to
respond to injury differently from the male heart. For example,
women have been reported to have less ventricular remodelling,
preservation of right ventricular function, and protection against
ventricular arrhythmias, neurohormonal activation, genetic muta-
tions, myocyte necrosis, and apoptosis.28 Some of these advan-
tages could be related to pregnancy28 and to sex-specific
differences in gene expression.29
In accordance with previous studies,13,14 we found lower pre-
scription of ACE inhibitors or ARBs in women than in men.
Perhaps surprisingly, this was particularly evident in patients with
reduced EF, where the evidence for these therapies is strongest.
In fact, for all age groups with reduced EF, women received ACE
inhibitors or ARBs less frequently than men (data not shown).
Given this pattern of prescribing, the lower risk of death for
women compared with men is all the more remarkable.
The reported prevalence of diabetes in patients with HF is highly
variable, with figures between 13% and 29%,20 –23probably due to
the definitions of both diabetes and HF used and the heteroge-
neous nature of the populations studied. Our data are consistent
with previous reports of higher risk of death among patients
with HF with co-existing diabetes.20223 In the current analysis
we have extended these previous observations to a large popula-
tion that included patients with reduced or preserved EF. In both
groups we observed diabetes to be a strong independent risk
factor for mortality in patients with HF. This association was par-
ticularly evident among women, especially those with reduced
EF, where the presence of diabetes attenuates the apparently pro-
tective ‘effect’ of female sex on prognosis. A similar interaction has
been described for patients with ischaemic heart disease, where
diabetes also attenuates the gender gap in mortality.30 In contrast,
female gender has been suggested to be associated with greater
likelihood of pre-clinical diabetic cardiomyopathy.31
Our finding that the association between female sex and better
survival appears to be stronger in patients with non-ischaemic HF
is in agreement with several previous studies.2,3,8 Importantly, we
have shown clearly that this sex-related difference in prognosis is
seen regardless of whether EF is reduced or preserved. A single
previous report, from the second Cardiac Insufficiency Bisoprolol
Study (CIBIS II), suggested no sex-related difference in mortality
in patients with non-ischaemic aetiology.9 However, in CIBIS II,
the aetiology of HF was undefined in 36% of men and 47% of
women, limiting markedly the ability of this trial to compare prog-
nosis between ischaemic and non-ischaemic HF.
Our analysis is constrained by the underlying limitations of the
original individual studies. However, by incorporating large
amounts of data from both randomized trials and observational
studies, resulting in a wide range of patients, with long follow-up
and a large number of clinical events, the results are likely to be
an accurate reflection of patients with the syndrome of HF seen
in routine clinical practice. The interaction between diabetes
status and sex-related outcomes is robust, whereas the interaction
with aetiology is less certain.
Conclusion
This analysis from a large, individual patient data meta-analysis has
demonstrated that women with HF have lower risk of death when
compared with men with HF, in both preserved and reduced EF.
This survival benefit may be more marked in HF of non-ischaemic
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aetiology but is clearly attenuated by concomitant diabetes.
Further study is required to determine the biological reasons for
this better prognosis in women.
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overall conduct of the meta-analysis): C. Berry, R.N. Doughty, C.
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gators from the original studies that provided individual patient data: A.
Ahmed, B. Andersson, A. Bayes-Genis, C. Berry, M. Cowie, R. Cubbon,
R.N. Doughty, J. Ezekowitz, J. Gonzalez-Juanatey, M. Gorini, I.
Gotsman, L. Grigorian-Shamagian, M. Guazzi, M. Kearney, L. Køber,
M. Komajda, A. di Lenarda, M. Lenzen, D. Lucci, S. Macı´n, B. Madsen,
A. Maggioni, M. Martı´nez-Selle´s, F. McAlister, F. Oliva, K. Poppe, M.
Rich, M. Richards, M. Senni, I. Squire, G. Taffet, L. Tarantini, C. Tribouil-
loy, R. Troughton, H. Tsutsui, G.A. Whalley.
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MAGGIC Statistical Group: J. Dobson, S. Pocock, K. Poppe.
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Andersson, C. Hall; BATTLESCARRED and Richards, A.M. Richards, R.
Troughton, J. Lainchbury; Berry, C. Berry, K. Hogg, J. Norrie, K. Steven-
son, M. Brett, J. McMurray; CHARM, M.A. Pfeffer, K. Swedberg, C.B.
Granger, P. Held, J.J.V. McMurray, E.L. Michelson, B. Olofsson, J. O¨sterg-
ren, S. Yusuf for the CHARM Investigators and Committees; Diamond
and ECHOS, L. Køber, C. Torp-Pedersen; DIG Trial, DIG limited access
data, Ali Ahmed; Euro HF Survey, M.J. Lenzen, W.J.M. Scholte op
Reimer, E. Boersma, P.J.M.J. Vantrimpont, F. Follath, K. Swedberg, J.
Cleland, M. Komajda; Gotsman, I. Gotsman, D. Zwas, D. Planer, T.
Azaz-Livshits, D. Admon, C. Lotan, A. Keren; Grigorian-Shamagian, L.
Grigorian-Shamagian, A. Varela-Roman, P. Mazo´n-Ramos, P. Rigeiro-
Veloso, M.A. Bandin-Dieguez, J.R. Gonzalez-Juanatey; Guazzi, M.
Guazzi, J. Myers, R. Arena; Heart Failure Clinic Edmonton, F.A. McAlister,
J. Ezekowitz, P.W. Armstrong, Bibiana Cujec, Ian Paterson; Hillingdon,
M.R. Cowie, D.A. Wood, A.J.S. Coats, S.G. Thompson, V. Suresh, P.A.
Poole-Wilson, G.C. Sutton; HOLA, M. Martı´nez-Selle´s, J.A.G. Robles, L.
Prieto, M.D. Mun˜oa, E. Frades, O. Dı´az-Castro, J. Almendral; Italian HF
Registry (IN-CHF), L. Tarantini, P. Faggiano, M. Senni, D. Lucci, D.
Bertoli, M. Porcu, C. Opasich, L. Tavazzi, A.P. Maggioni; Kirk, V. Kirk,
M. Bay, J. Parner, K. Krogsgaard, T.M. Herzog, S. Boesgaard, C. Hassager,
O.W. Nielsen, J. Aldershvile, H. Nielsen, L. Kober; Macin, S.M. Macı´n, E.R.
Perna; J.P. Cimbaro Canella; P. Alvarenga, R. Pantich, N. Rı´os, E.F. Farias,
J.R. Badaracco; Madsen, B.K. Madsen, J.F. Hansen, K.H. Stokholm, J. Brons,
D. Husum, L.S. Mortensen; MUSIC, A. Bayes-Genis, R. Vazquez, T. Puig,
C. Fernandez-Palomeque, A. Bardajı´, D. Pascual-Figal, J. Ordon˜ez-Llanos,
M. Valdes, A. Gabarrus, R. Pavon, L. Pastor, J.R. Gonzalez-Juanatey, J.
Almendral, M. Fiol, V. Nieto, C. Macaya, J. Cinca, A. Bayes de Luna;
Newton, J.D. Newton, H.M. Blackledge, I.B. Squire; NPC I, S.P. Wright,
G.A. Whalley, R.N. Doughty; Rich (data set 1), R. Kerzner, B.F. Gage,
K.E. Freedland, M.W. Rich; Rich (data set 2), B.C. Huynh, A. Rovner,
K.E. Freedland, R.M. Carney, M.W. Rich; Taffet: G.E. Taffet, T.A. Teasdale,
A.J. Bleyer, N.J. Kutka, R.J. Luchi; Tribouilloy, C. Tribouilloy, D. Rusinaru,
H. Mahjoub, V. Soulie`re, F. Le´vy, M. Peltier; Tsutsui, H. Tsutsui, M. Tsu-
chihashi, A. Takeshita; UK Heart Study, P.A. MacCarthy, M.T. Kearney,
R. Cubbon, J. Nolan, A.J. Lee, R.J. Prescott, A.M. Shah, W.P. Brooksby,
K.A.A. Fox; Varela-Roman: A. Varela-Roman, J.R. Gonzalez-Juanatey, P.
Basante, R. Trillo, J. Garcia-Seara, J.L. Martinez-Sande, F. Gude.
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